Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Coronary thrombolysis with defibrase].

T D Li1, L Y Gai, S R Wang

  • 1Department of Cardiology, PLA General Hospital.

Zhonghua Nei Ke Za Zhi
|February 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Dietary serine supplementation inhibits the hepatic macrophage AKT/mTOR pathway and improves primary biliary cholangitis].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology·2026
Same author

[In vitro experiment on the removal of fenthion and its metabolites by fat emulsion combined with hemoperfusion based on orthogonal design].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases·2026
Same author

[Whole-course management of abdominal opening with enteroatmospheric fistula].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery·2025
Same author

[Current status and future of application of spinal surgery robot in spinal deformity surgery].

Zhonghua yi xue za zhi·2024
Same author

[Clinical outcome of posterior lumbar interbody fusion combined with Ponte osteotomy for reconstruction of coronal sagittal plane balance in degenerative scoliosis].

Zhonghua yi xue za zhi·2024
Same author

[Application of endoluminal vacuum-assisted closure device in the treatment of gastrointestinal fistula].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery·2023

Defibrase (DF), a novel fibrinolytic agent, demonstrated significant recanalization in acute myocardial infarction (AMI) patients. Early DF infusion offers a high vessel patency rate with manageable bleeding risks.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Acute myocardial infarction (AMI) remains a leading cause of mortality worldwide.
  • Effective thrombolytic therapy is crucial for restoring blood flow and preserving cardiac function in AMI.
  • Current treatments have limitations, necessitating the investigation of novel agents.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of defibrase (DF), a fibrinolytic agent derived from Agkistrodon acutus venom, in patients with AMI.
  • To assess the impact of DF on coronary artery recanalization and left ventricular ejection fraction (LVEF) in AMI patients.

Main Methods:

  • A randomized controlled trial comparing conventional therapy plus DF with conventional therapy alone in AMI patients.
  • Patients received intravenous DF at specific dosages immediately after symptom onset and on subsequent days.

Related Experiment Videos

  • Coronary angiography and left ventriculography were performed to assess recanalization rates and LVEF.

    • Main Results:

    • High recanalization rates were observed in the DF group (10/10 patients) compared to the control group (3/11 patients).
    • Left ventricular ejection fraction (LVEF) was higher in the DF group (61%) versus the control group (50%), though not statistically significant.
    • Minor bleeding complications, including petechia and transient thrombocytopenia, occurred in the DF group, with no severe hemorrhages reported.

    Conclusions:

    • Defibrase (DF) exhibits significant thrombolytic and anticoagulant properties in AMI patients.
    • Early administration of DF leads to a high rate of coronary artery patency and shows a trend towards preserving left ventricular function.
    • DF presents a promising therapeutic option for AMI with a generally favorable safety profile regarding bleeding complications.